{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:18:09Z","timestamp":1791476289707,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Increased serum adenosine deaminase (ADA) levels have been shown to be involved in metabolic abnormalities and immune disequilibrium, which may in turn contribute to inflammatory diseases. This study aimed to determine whether increased serum ADA levels are related to diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes (T2D).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was part of a series exploring the potential risks for DPN. All patients received DPN assessment based on neuropathic symptoms, neuropathic signs, and nerve conduction studies to calculate the composite<jats:italic>Z<\/jats:italic>score of nerve latency, amplitude and conduction velocity (NCV). DPN was confirmed by both at least a presentation of neuropathic symptoms\/signs and an abnormal nerve conduction index. Serum ADA levels were also synchronously detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 384 eligible patients with T2D were recruited for this study, and 24.5% (n=94) were determined to have DPN. Increases in serum ADA levels were closely associated with increases in composite<jats:italic>Z<\/jats:italic>score of latency (<jats:italic>\u03b2<\/jats:italic>=0.263,<jats:italic>t<\/jats:italic>=5.273,<jats:italic>p<\/jats:italic>&amp;lt;0.001) and decreases in composite<jats:italic>Z<\/jats:italic>score of amplitude (<jats:italic>\u03b2<\/jats:italic>=\u20130.126,<jats:italic>t<\/jats:italic>=\u20132.352,<jats:italic>p<\/jats:italic>=0.019) and NCV (<jats:italic>\u03b2<\/jats:italic>=\u20130.201,<jats:italic>t<\/jats:italic>=\u20133.841,<jats:italic>p<\/jats:italic>&amp;lt;0.001) after adjusting for other clinical covariates. Moreover, each 5 U\/L increase in serum ADA levels was associated with a 1.781-fold increased adjusted odds ratio of having DPN (95% confidence interval: 1.271\u20132.495). Furthermore, the optimal cut-off value of serum ADA levels to discriminate DPN was \u226514.2 U\/L (sensitivity=59.57%, specificity=75.52% and Youden index=0.351) after analysis by receiver operating characteristic curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Increased serum ADA levels may be a potential risk factor for DPN in patients with T2D.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.997672","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T04:38:02Z","timestamp":1664858282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Chao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-yan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30081-6","article-title":"Diabetic peripheral neuropathy: Advances in diagnosis and strategies for screening and early intervention","volume":"7","author":"Selvarajah","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0142","article-title":"Diabetic neuropathies: clinical manifestations and current treatment options","volume":"2","author":"Vinik","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2463","article-title":"The relationship between brain volume and walking outcomes in older adults with and without diabetic peripheral neuropathy","volume":"35","author":"Manor","year":"2012","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2610","article-title":"Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy","volume":"37","author":"Selvarajah","year":"2014","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S312021","article-title":"Connecting peripheral to central neuropathy: Examination of nerve conduction combined with olfactory tests in patients with type 2 diabetes","volume":"14","author":"Ni","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000991","article-title":"Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease","volume":"8","author":"Mayeda","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0082","article-title":"Burden of diabetic peripheral neuropathy in pima indians with type 2 diabetes","volume":"39","author":"Jaiswal","year":"2016","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03697.x","article-title":"Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea","volume":"29","author":"Won","year":"2012","journal-title":"Diabetes Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0399-1","article-title":"Diabetic peripheral neuropathy as a predictor of asymptomatic myocardial ischemia in type 2 diabetes mellitus: A cross-sectional study","volume":"33","author":"Baltzis","year":"2016","journal-title":"Adv Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(16)30063-8","article-title":"Early recognition of diabetic peripheral neuropathy and the need for one-stop microvascular assessment","volume":"4","author":"Vas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1128(200103)21:2<105::aid-med1002>3.0.co;2-u","article-title":"Adenosine deaminase: functional implications and different classes of inhibitors","volume":"21","author":"Cristalli","year":"2001","journal-title":"Med Res Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.3390\/molecules25204652","article-title":"Therapeutic perspectives of adenosine deaminase inhibition in cardiovascular diseases","volume":"25","author":"Kutryb-Zajac","year":"2020","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/cvr\/cvw203","article-title":"Increased activity of vascular adenosine deaminase in atherosclerosis and therapeutic potential of its inhibition","volume":"112","author":"Kutryb-Zajac","year":"2016","journal-title":"Cardiovasc Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-012-9322-7","article-title":"Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of chagas disease","volume":"8","author":"Souza Vdo","year":"2012","journal-title":"Purinergic Signal"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/bf00789447","article-title":"Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs","volume":"90","author":"McClanahan","year":"1995","journal-title":"Basic Res Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111273","article-title":"Diabetes and hypertension: Pivotal involvement of purinergic signaling","volume":"137","author":"Reichert","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3109\/10641969809052125","article-title":"Effects of adenosine deaminase inhibition on blood pressure in old spontaneously hypertensive rats","volume":"20","author":"Tofovic","year":"1998","journal-title":"Clin Exp Hypertens"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ec-21-0344","article-title":"The association between serum adenosine deaminase levels and graves' disease","volume":"10","author":"Lu","year":"2021","journal-title":"Endocr Connect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0168-8227(94)90034-5","article-title":"Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus","volume":"25","author":"Hoshino","year":"1994","journal-title":"Diabetes Res Clin Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00496-z","article-title":"Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy","volume":"17","author":"Sloan","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"(2) classification and diagnosis of diabetes","year":"2015","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-018-0693-0","article-title":"HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients","volume":"17","author":"Su","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12020-018-1546-z","article-title":"Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients","volume":"60","author":"Hu","year":"2018","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13098-022-00795-z","article-title":"Plasma 1,5-anhydro-D-glucitol is associated with peripheral nerve function and diabetic peripheral neuropathy in patients with type 2 diabetes and mild-to-moderate hyperglycemia","volume":"14","author":"Xu","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/138945012800564095","article-title":"Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders","volume":"13","author":"Antonioli","year":"2012","journal-title":"Curr Drug Targets"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102709","article-title":"The roles of adenosine deaminase in autoimmune diseases","volume":"20","author":"Gao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.14670\/hh-18-404","article-title":"Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders","volume":"37","author":"Hall","year":"2022","journal-title":"Histol Histopathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2015.1065228","article-title":"Does adenosine deaminase activity play a role in the early diagnosis of ectopic pregnancy","volume":"36","author":"Turkmen","year":"2016","journal-title":"J Obstet Gynaecol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-009-1148-3","article-title":"Serum adenosine deaminase activity in gestational diabetes mellitus and normal pregnancy","volume":"281","author":"Mokhtari","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2016.09.004","article-title":"Elevated circulatingadenosine deaminase activity in women with preeclampsia: association with pro-inflammatory cytokine production and uric acid levels","volume":"6","author":"Giorgi","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.191124","article-title":"Adenosine deaminase as a useful biomarker for diagnosis and monitoring of inflammatory bowel disease","volume":"66","author":"Yordanova","year":"2020","journal-title":"Clin Lab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0026-0495(99)90187-7","article-title":"Adenosine deaminase and body mass index in non-insulin-dependent diabetes mellitus","volume":"48","author":"Bottini","year":"1999","journal-title":"Metabolism"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0697-4","article-title":"Maternal circulating levels of some metabolic syndrome biomarkers in gestational diabetes mellitus","volume":"51","author":"Khosrowbeygi","year":"2016","journal-title":"Endocrine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/1076029621999722","article-title":"Serum adenosine deaminase as a useful marker to estimate coronary artery calcification in type 2 diabetes mellitus patients","volume":"27","author":"Yu","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"B38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12902-018-0284-9","article-title":"Adenosine deaminase activity in type 2 diabetes mellitus: does it have any role","volume":"18","author":"Niraula","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13098-021-00671-2","article-title":"Inverse relationship between serum adenosine deaminase levels and islet beta cell function in patients with type 2 diabetes","volume":"13","author":"Cao","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.05.023","article-title":"Potential roles of adenosine deaminase-2 in diabetic retinopathy","volume":"436","author":"Elsherbiny","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1530\/ec-21-0306","article-title":"Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients","volume":"10","author":"Lu","year":"2021","journal-title":"Endocr Connect"},{"key":"B42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1530\/EC-21-0199","article-title":"The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients","volume":"10","author":"Lu","year":"2021","journal-title":"Endocr Connect"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-6-139","article-title":"The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c","volume":"6","author":"Xu","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/b978-0-444-53480-4.00001-1","article-title":"Epidemiology of polyneuropathy in diabetes and prediabetes","volume":"126","author":"Ziegler","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00090","article-title":"HbA1C variability is strongly associated with the severity of peripheral neuropathy in patients with type 2 diabetes","volume":"13","author":"Lai","year":"2019","journal-title":"Front Neurosci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108289","article-title":"TIR generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes","volume":"166","author":"Li","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(12)70065-0","article-title":"Diabetic neuropathy: clinical manifestations and current treatments","volume":"11","author":"Callaghan","year":"2012","journal-title":"Lancet Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.diabres.2016.02.005","article-title":"Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy","volume":"115","author":"Ge","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2259","article-title":"Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4\/FF4 study","volume":"40","author":"Herder","year":"2017","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.05.008","article-title":"Neutrophil-to-lymphocyte ratio is associated with diabetic peripheral neuropathy in type 2 diabetes patients","volume":"130","author":"Liu","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e106935","DOI":"10.1371\/journal.pone.0106935","article-title":"Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: a cross-sectional study","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.012228","article-title":"Evaluation of plasma adenosine as a marker of cardiovascular risk: Analytical and biological considerations","volume":"8","author":"Simard","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.156.4.1349","article-title":"Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response","volume":"156","author":"Dong","year":"1996","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00106","article-title":"Molecular evidence of adenosine deaminase linking adenosine A(2A) receptor and CD26 proteins","volume":"9","author":"Moreno","year":"2018","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501050102","article-title":"CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse","volume":"102","author":"Pacheco","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1109764","article-title":"Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages","volume":"88","author":"Zavialov","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2011.12.004","article-title":"Insulin resistance in the nervous system","volume":"23","author":"Kim","year":"2012","journal-title":"Trends Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.997672\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:11:25Z","timestamp":1677017485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.997672\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":58,"alternative-id":["10.3389\/fendo.2022.997672"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.997672","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"article-number":"997672"}}